Amphetamine News and Research RSS Feed - Amphetamine News and Research

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial. [More]
New U-M poll shows 1 in 100 parents believe their kids use prescription stimulants to boost grades

New U-M poll shows 1 in 100 parents believe their kids use prescription stimulants to boost grades

As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug" -- a prescription stimulant or amphetamine -- to gain an academic edge. But a new University of Michigan poll shows only one in 100 parents of teens 13-17 years old believes that their teen has used a study drug. [More]
Students receive Addiction Science Award at 2013 Intel International Science and Engineering Fair

Students receive Addiction Science Award at 2013 Intel International Science and Engineering Fair

An exploration of electronic "screen time" and sleep on mood, memory and learning was given the top Addiction Science Award at the 2013 Intel International Science and Engineering Fair - the world's largest science competition for high school students. [More]
Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013. [More]
New research may shed light on alcohol addiction vulnerability in some people

New research may shed light on alcohol addiction vulnerability in some people

A Wake Forest Baptist Medical Center team studying alcohol addiction has new research that might shed light on why some drinkers are more susceptible to addiction than others. [More]
Combination of two environmental factors contributes to schizophrenia

Combination of two environmental factors contributes to schizophrenia

The interplay between an infection during pregnancy and stress in puberty plays a key role in the development of schizophrenia, as behaviourists from ETH Zurich demonstrate in a mouse model. However, there is no need to panic. [More]
Annual deaths related to heroin and morphine continue to drop in the UK

Annual deaths related to heroin and morphine continue to drop in the UK

Annual deaths related to heroin and morphine are continuing to drop significantly, falling from 41 per cent of total drug-related deaths in the UK in 2010 to 32 per cent in 2011. Meanwhile, deaths from 'legal highs' - some of which have now been banned - remained steady following a large increase in the previous year. [More]
Modafinil may help some people to reduce drinking by improving their impulse control

Modafinil may help some people to reduce drinking by improving their impulse control

Poor impulse control contributes to one's inability to control the consumption of rewarding substances, like food, alcohol, and other drugs. This can lead to the development of addiction. FDA-approved medications for alcoholism, like naltrexone (Revia) and disulfiram (Antabuse), are thought to reduce alcohol consumption by curbing cravings and creating unpleasant reactions to alcohol, effects which reduce the desire to drink alcohol. [More]
Social isolation increases risk of addiction to amphetamine and alcohol

Social isolation increases risk of addiction to amphetamine and alcohol

Rats that are socially isolated during a critical period of adolescence are more vulnerable to addiction to amphetamine and alcohol, found researchers at The University of Texas at Austin. Amphetamine addiction is also harder to extinguish in the socially isolated rats. [More]
NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

Continued high use of marijuana by the nation's eighth, 10th and 12th graders combined with a drop in perceptions of its potential harms was revealed in this year's Monitoring the Future survey, an annual survey of eighth, 10th, and 12th-graders conducted by researchers at the University of Michigan. [More]
Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition. [More]
MH6 vaccine shows promise in treating meth addiction

MH6 vaccine shows promise in treating meth addiction

Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication. [More]
Exendin-4 could effectively treat addiction

Exendin-4 could effectively treat addiction

Vanderbilt researchers are reporting today that a drug currently used to treat type 2 diabetes could be just as effective in treating addiction to drugs, including cocaine. [More]
Mephedrone and memory loss: an interview with Craig Motbey

Mephedrone and memory loss: an interview with Craig Motbey

Mephedrone is a fairly new designer drug which has been around for a few years. It exploded in popularity in Europe (and particularly in the UK) before it started to spread in a major way elsewhere. [More]
FTC votes to approve Watson's acquisition of Actavis

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies. [More]
Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD. [More]
Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). [More]
Scientists analyze raw sewage samples to determine illicit drug use

Scientists analyze raw sewage samples to determine illicit drug use

Surveys of drug use form an important basis for the development of effective drug policies, and also for measuring the effectiveness of existing policies. For the first time in history, scientists have now made direct comparisons of illicit drug use in 19 European cities by a cooperative analysis of raw sewage samples. [More]
Raising dopamine levels in frontal cortex reduces impulsivity in healthy adults

Raising dopamine levels in frontal cortex reduces impulsivity in healthy adults

Raising levels of the neurotransmitter dopamine in the frontal cortex of the brain significantly decreased impulsivity in healthy adults, in a study conducted by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco. [More]
HIV in MSM increasing in countries of all incomes

HIV in MSM increasing in countries of all incomes

A new Lancet Series published to coincide with the AIDS2012 meeting highlights a population where the HIV epidemic is growing in countries of all incomes: men who have sex with men (MSM). The first paper in the Series charts the epidemiology of HIV among MSM, and is by Professor Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, and colleagues. [More]